Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of intravitreal ANX007 for dry age-related macular degeneration with geographic atrophy
NL-OMON60470Phase 3Active, not recruiting
- Sponsor
- Annexon Biosciences
- Start
- May 2025
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of vonaprument in age-related macular degeneration (AMD) and geographic atrophy (GA) (2 arms), sponsored by Annexon Biosciences. Primary endpoint: Confirmed BCVA loss of at least 15 letters through Month 15. Started May 2025; status: active, not recruiting.
02
Drugs
vonaprument
03
Conditions
age-related macular degeneration (AMD)geographic atrophy (GA)
Beyond the preview
Go deeper on NL-OMON60470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60470.